Beranda › Kanker Kolorektal › Wisconsin › Madison
Uji klinis Kanker Kolorektal di Madison, WI
23 studi untuk Kanker Kolorektal mencari peserta di lokasi sekitar Madison (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
Menerima pesertaFase 2
- University of Wisconsin, Madison
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Menerima pesertaFase 1/2
- University of Wisconsin Carbone Cancer Center, Madison
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Menerima pesertaFase 2
- UW Health Carbone Cancer Center, Madison
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- William S Middleton VA Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Menerima pesertaFase 1
- Wisconsin Institute for Medical Research, Madison
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Menerima pesertaFase 1/2
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Menerima pesertaFase 1/2
- University Hospital and UW Health Clinics-Carbone Cancer Center ( Site 0293), Madison
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Menerima pesertaFase 3
- William S. Middleton Memorial VA, Madison
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Menerima pesertaFase 3
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Menerima pesertaFase 2
- Research Site, Madison
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Menerima pesertaFase 1
- University of Wisconsin - Carbone Cancer Center, Madison
Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
Menerima pesertaFase 2
- University of Wisconsin Carbone Cancer Center, Madison
An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis
Menerima pesertaFase 2
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Menerima pesertaFase 3
- Clinical Study Site, Madison
A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)
Menerima pesertaFase 1
- Univ of Wisconsin-Madison, Madison
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Menerima pesertaFase 1
- University of Wisconsin - Carbone Cancer Center, Madison
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1/2
- University of Wisconsin, Carbone Cancer Center, Madison
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
- University of Wisconsin- Madison, Madison
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Menerima pesertaFase 1/2
- GSK Investigational Site, Madison
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Menerima pesertaFase 1/2
- University of Wisconsin, Madison
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Menerima pesertaFase 1
- University of Wisconsin (Carbone Cancer Center), Madison
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Menerima pesertaStudi observasional
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Menerima pesertaFase 4
- University of Wisconsin, Madison
Uji klinis Kanker Kolorektal di kota lain
- Houston, TX102 studi
- New York City, NY78 studi
- Nashville, TN69 studi
- Boston, MA63 studi
- Los Angeles, CA59 studi
- Arlington, VA52 studi
- St. Louis, MO50 studi
- San Antonio, TX46 studi
- Philadelphia, PA44 studi
- Grand Rapids, MI40 studi
- Baldwin Park, CA37 studi
- Chicago, IL34 studi
Studi lain di Madison
- Kanker Prostat29 studi
- Kanker Payudara22 studi
- Kanker Metastatik21 studi
- Leukemia Mieloid Akut16 studi
- Kanker Paru Non-Sel Kecil16 studi
- Melanoma15 studi
- Kanker (semua jenis)14 studi
- Kanker Ovarium13 studi
- Kanker Lambung11 studi
- Kanker Pankreas10 studi
- Kanker Paru10 studi
- Mieloma Multipel9 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.